Publications by authors named "I Walter-Sack"
Background: The antimalarial artesunate (ART), a semisynthetic derivative of artemisinin from the Chinese herb artemisia annua has remarkable anticancer properties in vitro and in vivo. Its excellent safety profile known from short-term therapy in malaria was confirmed in an open phase I trial (ARTIC M33/2) for dose-finding as add-on therapy for four weeks.
Purpose: Patients with metastatic breast cancer, who had not experienced any clinically relevant adverse events (AE) during participation in ARTIC M33/2, were offered to continue ART as compassionate use (CU).
Purpose: The antimalarial drug artesunate (ART) is a promising candidate for cancer treatment as it displays anticancer effects in various models. While in short-term treatment of malaria, an excellent safety profile has been found for ART, the potential long-term treatment of cancer patients demands a phase I dose-finding clinical trial determining the daily ART dose which would be well tolerated as add-on therapy.
Methods: Patients with metastatic breast cancer were to receive either 100 or 150 or 200 mg oral ART daily as add-on to their guideline-based oncological therapy for a study period of four weeks with frequent clinical and laboratory monitoring until 4-8 weeks thereafter.
Purpose: Artesunate (ART) has been used for a long time in the treatment of Plasmodium falciparum malaria and has been considered safe. The present phase I study aimed to determine the daily dose of ART that is well tolerated as add-on therapy in patients with breast cancer for 4 weeks of therapy. Ototoxicity could be a potential safety concern in settings different from malaria.
View Article and Find Full Text PDFArticle Synopsis
- Methylene blue (MB) is being researched for its effects when added to malaria treatment, particularly regarding safety in patients with G6PD deficiency, which can lead to haemolysis.
- A pooled analysis from clinical studies on West African children with falciparum malaria indicated that MB dosage and G6PD genotype significantly affect haemoglobin levels.
- While MB treatment may cause some reduction in haemoglobin for G6PD-deficient children, the clinical impact appears limited, though ongoing monitoring of these patients is necessary.